Ethaselen

乙烷硒啉

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameEthaselen
Drug Alias NameCompound EbBBSKEEb-1
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionThioredoxin reductase inhibitors
TargetsThioredoxin reductase
Therapy Area/IndicationsSolid tumoursHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPeking UniversityKaixi Pharmaceutical (Wuhan) Co LtdCheezheng Tibetan Medicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesPeking UniversityKaixi Pharmaceutical (Wuhan) Co LtdCheezheng Tibetan Medicine Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A